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High triglycerides levels have been consistently linked to risk of cardiovascular disease,1 with mounting evidence 
supporting their causal role in the progression of the disease.2–5 
In moderately raised concentrations (2–10 mml/L),6 triglycer-
ides appear to be able to penetrate the arterial intima7 where 
they are trapped within the arterial wall contributing to athero-
sclerosis.8 In the fasting state, circulating triglycerides are trans-
ported in large, medium, and small particles of very low–density 
lipoproteins (VLDLs) and their remnants after lipolysis and 
remodeling,9 mainly in the form of small VLDLs and interme-
diate-density lipoproteins. Smaller percentages of triglyceride 
can also be found in low-density lipoprotein (LDL; <10%) and 
high-density lipoprotein (HDL; ≈15%) particles.10 In postpran-
dial conditions, chylomicrons and their remnants account for a 
large proportion of the elevated triglyceride levels.11
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A common component of triglyceride-rich lipoproteins is 
apolipoprotein C-III (APOC3). APOC3 is a small 99 amino 
acid peptide12 coded by the APOC3 gene located on chromo-
some 11, between and in close proximity to the APOA4 and 
APOA1 genes.13 Recent advances in genetic data collection 
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have permitted the study of low minor allele frequency vari-
ants (<5% minor allele frequencies) which have, potentially, 
strong associations with phenotypes. Through these methods, 
a rare loss of function single nucleotide variant rs138326449 
that changes the splicing of the APOC3 gene10,14–16 has been 
identified. The rare allele of this single nucleotide variant has 
been associated with a substantial decrease in the risk of coro-
nary artery disease,10,15 varying levels of reduction in triglycer-
ide of 0.5 to 1.5 mmol/L depending on the population studied 
and evidence of changes to VLDL and HDL levels.16
APOC3 is involved in several intra- and extracellular 
mechanisms, including the production and clearance of 
triglyceride-rich lipoproteins from circulation. The effect of 
APOC3 on triglyceride and remnant particles, smaller and 
denser remodeled triglyceride-rich particles with some of 
their triglyceride removed, is suggested to operate mainly 
through the inhibition of triglyceride-rich lipoproteins hydro-
lysis by lipoprotein lipase (LPL)17 and a subsequent attenu-
ation of uptake into hepatocytes.12 LPL polymorphisms have 
been associated with levels of both triglyceride and HDL18 
and also with risk of coronary artery disease.19 To date, epi-
demiological studies have not had the required information 
to assess the molecular mechanisms involved, and despite 
the consensus that APOC3 is affecting the TLRs, small in 
vivo and in vitro studies have not determined the relative 
importance of the different mechanisms20 and how specific 
mutations of the APOC3 gene can affect these processes.21
Here we use data from 2 well-characterized European 
population cohort studies to provide a detailed profile of 
the associations between the rare and poorly characterized 
APOC3 genetic variant rs138326449 and individual lipopro-
tein subclasses that might contribute to atherosclerosis risk. 
For this, we used a targeted metabolomics approach measur-
ing, among others, the size and composition of 14 lipoprotein 
subclasses. This approach has previously been used to charac-
terize the molecular profile of common diseases, identify new 
biomarkers, and study the genetic basis of systemic metabo-
lism (reviewed in Soininen et al22). We aimed to characterize 
in greater detail the impact of variation at this locus and its role 
in triglyceride metabolism as seen from an epidemiological 
perspective, including elucidating APOC3’s LPL-dependent 
and LPL-independent actions on the levels and composition 
of specific lipoprotein particles, as well as the mechanism of 
action of a recently proposed APOC3 inhibitor for the treat-
ment of hypertriglyceridemia.
Methods
Study Populations
The Avon Longitudinal Study of Parents and Children (ALSPAC) is 
a population-based, prospective birth cohort (www.bris.ac.uk/alspac). 
The study initially invited >14 000 pregnancies and has since fol-
lowed participants in several phases during development and maturi-
ty. Information on the phases can be found at www.bris.ac.uk/alspac/
researchers/resources-available/data-details/data-tables/documents/
focusclinicsessions.pdf. Full details of the study have been published 
previously, and here focus is on the offspring of this study (herein 
referred to as young participants) and their mothers.23 Ethical ap-
proval for the study was obtained from the ALSPAC Ethics and Law 
Committee and from the UK National Health Service Local Research 
Ethics Committees. Participants have provided informed consent for 
the use of the data.
Analyses were also undertaken in an independent cohort of wom-
en. The British Women Heart Health Study (BWHHS) is a prospec-
tive cohort study that recruited women between the ages of 60 and 79 
years from 23 towns across the United Kingdom between 1999 and 
2001 and has followed those women forward through record linkage 
and detailed questionnaires since that time.24 Ethical approval for the 
study was obtained from the UK National Health Service Research 
Ethics Committees, and participants provided informed consent.
Serum Nuclear Magnetic Resonance Metabolomics
A high-throughput serum nuclear magnetic resonance metabolomics 
platform was used to quantify ≤233 metabolic measures that repre-
sent a broad molecular signature of systemic metabolism.22,25 The 
measured set covers multiple metabolic pathways, including lipopro-
tein lipids and subclasses, fatty acids and fatty acid compositions, as 
well as amino acids and glycolysis precursors. All molecular mea-
sures are quantified in a single experimental setup, constituting both 
established and novel metabolic risk factors.22 The applied nuclear 
magnetic resonance–based metabolic profiling has recently been 
used in various epidemiological and genetic studies.26–31 Applications 
of this high-throughput metabolomics platform has recently been 
reviewed,22 and details of the experimentation have been described 
elsewhere.25,32
For the ALSPAC young participants, metabolic measures were 
obtained from serum taken at follow-up clinic assessments at the 
approximate ages of 7, 15, and 17 years. In total, 7176 participants 
had at least one measurement, with 1453 measured at all 3 ages. For 
73 sibling pairs, one child was removed at random before statistical 
analysis. Samples from the 15- and 17-year follow-up assessments 
were taken after overnight fast, for those assessed in the morning, and 
at least 6-hour fast for those assessed after 14.00 hours; samples tak-
en at the 7-year assessment were nonfasted. To allow the maximum 
sample size for analyses (given the relative stability of fasting versus 
nonfasting samples33), data were taken from all available time points. 
However, to minimize unnecessary heterogeneity, where participants 
had repeat measurements, we prioritized those collected under fasted 
conditions. This led to a final analysis sample with 37.5% nonfasting 
(sensitivity analyses excluding those nonfasting are provided in the 
Data Supplement).
Measurements were available for 4530 ALSPAC mothers at a me-
dian age of 48 years (with an overlap of 1981 mothers of the young 
participant sample). All of the samples from the ALSPAC mothers 
were taken after an overnight fast for those taken in the morning and 
a minimum 6-hour fast for those taken after 14.00 hours.
Samples were available for 3780 women from the BWHHS at 
baseline assessment (age 60–79 years) after an overnight fast for 
those assessed in the morning and a minimum of 6-hour fast for those 
assessed after 14.00 hours. Given differences in storage of the sam-
ples between studies, 225 metabolites were common in all 3 and are 
used here.
Genotyping
Genotyping for the rs138326449 splice variant APOC3 mutation was 
performed using KASPAR at KBioscience (www.lgcgenomics.com) 
for all participants from both studies who had a suitable DNA sample. 
Genotypes for the leading triglyceride-associated LPL singe nucleotide 
polymorphism (SNP) rs12678919, a downstream intergenic variant in 
linkage disequilibrium with an SNP with previous evidence of tran-
scriptional regulation,34 were extracted from the existing genome-wide 
common variant data available in ALSPAC.35 For BWHHS, the SNP 
was extracted from the available Metabochip array data.36 Standard 
metrics were used to assess the quality of these data (missingness 
[>3%], non-European ancestry, and SNPs of minor allele frequency of 
<1%, call rate of <95%, and Hardy–Weinberg equilibrium [P<5×10−7]).
Statistical Analysis
The metabolic measures were inspected for deviations from normal-
ity and transformed, when needed, using the natural logarithm plus 
one to be consistent throughout because some metabolic measures 
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included zero values. For the analysis of the association between the 
metabolic measures and rs138326449(APOC3), we used a linear re-
gression model adjusting for age, sex and, to try to adjust for the non-
fasting measurements at age 7, as well as any other differences related 
to handling and storage of the blood samples, an indicator variable for 
the phase of measurement where relevant. Primary analysis was un-
dertaken in the ALSPAC young participants. Meta-analyzed results, 
from a fixed-effects model, of ALSPAC mothers and BWHHS were 
generated in parallel to those from the ALSAPC offspring. This first 
approach was taken as the comparison of results from these sample 
sources permits the confirmation of observed results, but the com-
plications of fasting status, age, and sex may complicate inference 
drawn from of a meta-analysis across all collections. Where overall 
meta-analysis was undertaken, we first pooled the ALSPAC mothers 
and young participants using a linear mixed-effects model to adjust 
for the pedigree correlation.37 Subsequently, we used a fixed-effect 
meta-analysis to combine the results of the pooled ALSPAC sample 
with the BWHHS women. To address the uncertainty caused by het-
erogeneity, we also used a random effects meta-analysis model, but 
because of the small number of study samples available, we consider 
this as a sensitivity analysis of the main fixed-effects results.38 We 
used the Benjamini and Yekutieli false discovery rate procedure under 
dependency39 to adjust the P values of the confirmation analysis for 
the associations reaching the 0.05 P value threshold in the discovery 
sample and all meta-analysis results for multiple testing as imple-
mented in the p.adjust package in R.
It is assumed that the APOC3 acts on triglyceride and VLDL 
largely through inhibition of LPL.12,17 We tested whether the APOC3 
variant associations with metabolites could be explained by the in-
hibition of LPL by using the genetic variant LPL(rs12678919) as a 
proxy of LPL protein levels.18 We estimated the predicted effect of 
APOC3 on the metabolites if this was exclusively through LPL by 
looking at the ratio of SNP associations between LPL(rs12678919) 
and the focus variant here APOC3(rs138326449). The model used the 
mean of the ratios of the effects of APOC3 and LPL genetic variants 
on each metabolite to obtain an estimate of the LPL-mediated effects 
of APOC3. To avoid the inclusion of metabolic measures that do not 
follow the assumed model of APOC3 action, we made use of the 25% 
trimmed mean as a true estimate of the effect of APOC3 on LPL. We 
bootstrapped the sample 1000 times to obtain the standard error of the 
mean of the ratios. The predicted effect of APOC3 on each metabolite 
was estimated as the product of the mean of the ratios and the LPL 
effect per metabolite, whereas the predicted confidence intervals were 
estimated taking into account the standard errors of both the LPL es-
timates and of the mean of the ratios. The absence of overlap in the 
coefficients between the predicted and observed APOC3 estimates 
were considered as evidence for an effect of APOC3 not mediated 
by its inhibition of LPL. We followed the same procedure in each of 
the parallel studies and combined their estimates using a fixed-effects 
meta-analysis weighted by their sample size.
Analyses were undertaken in Stata (Stata Statistical Software: 
Release 13. College Station, TX: StataCorp LP) and R 3.1.040 and 
plots prepared using ggplot2.41
Results
APOC3(rs138326449) was present with minor allele frequen-
cies of 0.20% to 0.28% in the 3 studies and adhered to Hardy–
Weinberg equilibrium. LPL(rs12678919) polymorphism was 
more common with a minor allele frequencies of 9.2% to 
10.6% across the 3 studies. Key characteristic of participants 
from each study are shown in Table 1.
Of the 225 metabolic measures available in all 3 studies, 
when analyzed in the ALSPAC young participants, 134 showed 
nominal evidence of association with APOC3(rs138326449; 
P≤0.05). APOC3(rs138326449) was associated with a 
decrease in triglyceride concentration (−0.11 mmol/L of geo-
metric mean, 95% confidence interval −0.16 to −0.05 mmol/L; 
P=2.57×10–4) and an increase of HDL (0.26 mmol/L, 95% 
confidence interval 0.18–0.34 mmol/L; P=2.4×10–6). More 
generally, APOC3(rs138326449) showed an effect on a broad 
range of measures reflecting the circulating levels and lipid 
composition of VLDL and HDL particles (Figure 1). A full 
table of results for all 225 measures can be found in Table I 
in the Data Supplement. A comparison of the results from the 
mixed fasting–nonfasting analysis used and analysis based on 
fasting and nonfasting measurements showed broadly simi-
lar association profiles, though there were differences in the 
nonfasting samples for specific measures of small HDL, very 
large VLDL, large LDL, remnant cholesterol, fatty acids, and 
glutamine (Table II in the Data Supplement).
In meta-analysis results of the ALSPAC mothers and 
BWHHS samples, 124 metabolic measures showed nominal 
evidence of association with APOC3(rs138326449) (P≤0.05; 
Table I in the Data Supplement), supporting 81 of the signals 
seen in the ALSPAC younger participants after adjustment 
for multiple testing (Table III in the Data Supplement). For 
both triglyceride and HDL, associations were stronger, but 
consistent with the young participant results (−0.23 mmol/L 
of geometric mean, 95% confidence interval −0.34 to −0.12 
mmol/L; P=4.6×10–6 and 0.4191 mmol/L, 95% confidence 
interval 0.28–0.56 mmol/L; P=1.74×10–9, respectively). In 
addition to the VLDL and HDL measures of concentration 
and composition, evidence for an increase of the ratio of ω-6, 
polyunsaturated and monounsaturated fatty acids to total fatty 
acid, were also confirmed. When all 3 samples were consid-
ered together, 118 associations were observed after adjustment 
for multiple testing, with 88 also showing evidence of asso-
ciation in the random-effects model. Associations in ALSPAC 
Table 1. Numbers of Individuals Measured and Key 
Characteristic of Samples Analyzed
ALSPAC Young 
Participants
ALSPAC  
Mothers BWHHS
N with NMR 
measurements
7176 4530 3646
N with NMR 
measurements and 
APOC3 information
6765 2463 3584
MAF of APOC3 % 0.20 0.26 0.28
N with NMR 
measurements and 
LPL information
5656 1953 1866
MAF of LPL 10.34 10.60 9.19
Sex (% females) 48.33 1 1
Age (years) (mean, 
interquartile range)
13.5 (7.5–17.7) 47.9 (45 - 51) 74.45 (70–79)
HDL mmol/L (mean, 
standard deviation)
1.44 (0.22) 1.69 (0.32) 1.67 (0.45)
TG mmol/L (geometric 
mean, untransformed 
standard deviation)
0.93 (0.18) 1.00 (0.24) 1.57 (0.31)
ALSPAC indicates The Avon Longitudinal Study of Parents and Children; 
APOC3, Apolipoprotein C-III; BWHHS, British Women Heart Health Study; HDL, 
high-density lipoprotein; LPL, lipoprotein lipase; MAF, minor allele frequency; 
NMR, nuclear magnetic resonance; and TG, triglyceride.
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young participants, meta-analysis of ALSPAC mothers and 
BWHHS, and the meta-analysis of all 3 samples are presented 
in Figure I in the Data Supplement, with details for each asso-
ciation in Table I in the Data Supplement.
The pattern of associations between LPL (rs12678919) and 
the metabolic measures was very similar to that observed for 
APOC3 (rs138326449; Figure 2). A Pearson’s correlation test 
between the coefficients of LPL (rs12678919), scaled by their 
Figure 1. APOC3(rs138326449) associations with selected metabolic measures in plasma in ALSPAC young participants and BWHHS–
ALSPAC mothers in Beta/SE units. The variant is associated predominately with very low–density lipoprotein (VLDL) and high-density lipoprotein 
(HDL) concentration and composition, as well as particle size, cholesterol measures, and fatty acids. Multiple associations per particle are rep-
resented by a single entry. Information on the transformation used is also provided. Estimates and confidence intervals were scaled by the stan-
dard error of each measurement. Plot of the association of all 225 measured metabolites is given in Figure I in the Data Supplement. A detailed 
list of effect sizes and P values for all measures is given Table I in the Data Supplement. ALSPAC indicates The Avon Longitudinal Study of 
Parents and Children; BWHHS, the British Women Heart Health Study; HDL, high-density lipoprotein; and IDL, intermediate-density lipoproteins.
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SE, and those obtained for the association of the metabolites 
with APOC3 (rs138326449) in the ALSPAC young participants 
shows strong correlation with r=0.88. In ALSPAC young par-
ticipants, a total of 126 metabolic measures showed nominal 
evidence of association with LPL (rs12678919; P≤0.05; Table 
IV in the Data Supplement). Of these associations, 90 were con-
firmed in the meta-analysis of ALSPAC mothers and BWHHS 
samples (false discovery rate adjusted P≤0.05; Table V in the 
Data Supplement). The meta-analysis of all 3 samples revealed 
113 associations (false discovery rate adjusted P≤0.05), with 75 
of them having evidence of association when a mixed-effects 
model was considered. All association results for the analyses 
can be seen in Table IV in the Data Supplement and plotted 
against the discovery effects in Figure II in the Data Supplement.
There was evidence for APOC3 effects being mediated 
through LPL in the majority of the metabolic measures con-
sidered. Of the 225 measures tested in the ALSPAC young 
participants, 6 had no overlapping 95% confidence intervals 
Figure 2. APOC3(rs138326449) and LPL(rs12678919) correlation of their respective associations with metabolic measures in plasma. The 
observed effects of LPL(rs12678919) are similar to those seen with APOC3(rs138326449). The black line is the line of perfect fit, whereas the 
blue line is the correlation between the 2 metabolic profiles of the 2 singe nucleotide polymorphism (SNPs) with slope equal to 0.87 for the 
ASPAC young participants. Estimates and confidence intervals were scaled by the standard error of each measurement. A detailed list of the 
association measures for all metabolites and the LPL(rs12678919) is given in Table II in the Data Supplement and plotted in Figure II in the Data 
Supplement. ALSPAC indicates The Avon Longitudinal Study of Parents and Children; and BWHHS, the British Women Heart Health Study.
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between the directly observed APOC3(rs138326449) effects 
and those predicted by LPL(rs12678919; Table VI in the 
Data Supplement). The ALSPAC mothers and the BWHHS 
results confirmed 2 of the suggested 6 APOC3-specific effects 
as independent from LPL (Table 2 and Figure 3). When all 
3 samples were combined, 8 measures showed evidence of 
nonoverlapping estimates (Table VI in the Data Supplement). 
Those measures which maintained evidence of an effect 
outside the action of LPL inhibition were both measures of 
VLDL composition characterizing the percentage of triglyc-
eride in very large and medium VLDL. All results on the com-
parison of the LPL predicted and observed APOC3 effects are 
provided in Table VI in the Data Supplement.
Discussion
Using detailed measures of lipoprotein subclass concentration 
and composition and several other metabolic measures, we pro-
vided a profile for the effect of the rare APOC3 (rs138326449) 
splice variant on mothers and young participants from one 
European population cohort and older adult women from an 
independent European population cohort. We confirmed the 
previously reported, but crudely assessed, association with tri-
glyceride, VLDL, and HDL16 levels and identified additional 
associations with VLDL and HDL composition, other choles-
terol measures, and fatty acids. Using LPL (rs12678919) as a 
proxy for LPL protein levels, we tested the extent to which 
APOC3 action on lipids is mediated through LPL inhibition.12,17 
Our results suggest that the great majority of the APOC3 effects 
are in line with the assumed mode of action through LPL; the 
composition of very large and medium VLDL particles involve 
other mechanisms in addition to LPL. Although the pathways 
involved have been previously studied in model organisms 
and in vitro experiments,21 here we present an epidemiological 
view of triglyceride metabolism in relation to APOC3 based 
on extensive metabolite measurements, many of which have 
not been previously studied in large epidemiological studies. 
Biological interpretation of the identified associations should 
thus be in the context of previously accumulated evidence in 
other experimental systems, many of which we were able to 
replicate here as also operating in humans.
Although the associations with total VLDL, HDL, and 
triglyceride levels were in the same direction as those in pre-
vious studies,10,15,16,42 their magnitude of effect was lower in 
the young participants. We did not find evidence for the asso-
ciations of APOC3 (rs138326449) with either intermediate-
density lipoproteins or LDL concentration or composition, 
with previous studies reporting contradictory effects on LDL 
for the rare APOC3 mutations15 and its mRNA inhibition.43 
Consideration of the fasting and nonfasting individuals in the 
young participants sample separately was consistent with the 
overall results of no association.
The greater resolution provided by the detail measurement 
of the lipoprotein subclasses shows that the effects of the splice 
variant on VLDL and HDL can be seen in almost the entire 
spectrum of their size. A highly similar pattern can be seen in 
the LPL associations with the metabolic measures. Also, both 
have an effect on the diameter of VLDL and HDL particles, 
with the rare allele associated with a decrease in the diameter 
of VLDL and an increase in the diameter of HDL particles in 
serum. For VLDL, lipoprotein kinetic studies have shown that 
the different size VLDL particles are metabolically heteroge-
neous,44 with large subfractions generating remnants that persist 
in circulation, whereas smaller VLDL particles are rapidly and 
efficiently converted to LDL,44 which agrees with our observa-
tions especially for the small VLDL and LDL measures.
Although the assumed mode of effect of APOC3 on tri-
glyceride levels and triglyceride-rich lipoproteins is because 
of impeded lipolytic conversion and hepatic clearance, in 
vivo and in vitro evidence point toward an additional role 
of APOC3 in the production of high triglyceride content 
VLDL (reviewed in Yao and Wang21). Our comparison of 
the APOC3 and LPL association revealed that the composi-
tion of medium and very large VLDL is not fully predicted 
by the action of APOC3 through LPL. Studies show that 
APOC3 expression promotes the assembly and secretion 
of the bigger triglyceride-rich VLDL from hepatocytes 
through the mobilization of endoplasmic reticulum/Golgi 
microsomes triglyceride for VLDL assembly.45 This intra-
cellular mechanism is manifest under conditions of insu-
lin resistance or hypertriglyceridemia,21 though our results 
suggest it also operates under normal conditions. Different 
structural changes in the APOC3 protein, either in the N 
Table 2. Observed and Predicted Effects of APOC3 on Metabolic Measures With Evidence of an LPL-Independent Mechanism
Young Participants ALSPAC Mothers and BWHHS
Observed Predicted Observed Predicted
Beta 
Coeff SE
Upper 
95% CI
Lower 
95% CI
Beta 
Coeff SE
Upper 
95% CI
Lower 
95% CI
Beta 
Coeff SE
Upper 
95% CI
Lower 
95% CI
Beta 
Coeff SE
Upper 
95% 
CI
Lower 
95% 
CI
Triglycerides to 
total lipids ratio 
in very large 
VLDL,* %
−0.297 0.062 −0.176 −0.419 −0.055 0.052 0.047 −0.156 −0.790 0.214 −0.371 −1.210 0.109 0.207 0.514 −0.295
Triglycerides to 
total lipids ratio in 
medium VLDL,* %
−0.049 0.015 −0.019 −0.078 0.019 0.014 0.045 −0.008 −0.179 0.027 −0.126 −0.233 −0.021 0.027 0.031 −0.073
ALSPAC indicates The Avon Longitudinal Study of Parents and Children; BWHHS, the British Women Heart Health Study; CI, confidence interval; LPL, lipoprotein lipase; and VLDL, 
very low–density lipoprotein.
*Measures have been transformed using an ln+1 transformation.
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or C terminals, affect the assembly and secretion of larger 
VLDL particles in different ways46,47 but have no effect on 
the triglyceride-poor smaller VLDL particles.
Our observations of a APOC3 LPL-independent triglycer-
ide-related pathway agree with Gaudet et al,48 testing the effects 
of an APOC3 mRNA inhibitor on familial chylomicronemia 
syndrome sufferers. In this case, deficiency in LPL leads to 
severe hypertriglyceridemia, which can result in recurrent and 
potentially fatal pancreatitis. When 3 patients were given an 
APOC3 inhibitor that lowered their APOC3 levels, a reduction 
of triglyceride was observed.48 Similar results were obtained 
in patients with severe or uncontrolled hypertriglyceridemia.43 
Although we did not find an LPL-independent effect on total 
serum triglyceride, either because of lack of statistical power 
or because of the differences between hypertriglyceridemia 
patients and the samples available here representing the gen-
eral population, the availability of more refined measures of 
triglyceride concentration in specific subclasses permitted 
the identification of the likely mechanism responsible for the 
effect of APOC3 inhibition. Our results point toward changes 
in the composition of VLDL and its proportion of triglycer-
ide though an intrahepatic pathway, rather than a mechanism 
involving changes in triglyceride absorption.
Our study has several limitations, mainly in relation to the 
differences in age and sex between the 3 study samples and 
the mix of fasting and nonfasting status in ALSPAC children. 
For these reasons, the ALSPAC mothers and BWHHS samples 
were only considered as able to confirm the common observed 
associations, with false positives indinguishable from hetero-
geneity between the samples because of age and sex for the 
discordant result. Fasting status in the ALSPAC young partici-
pants was addressed through a sensitivity analysis excluding 
nonfasting individuals, with no evidence of an effect that can 
change our conclusions. Finally, the low number of the rare 
APOC3(rs138326449) variant carriers might have contributed 
to the no identification of true associations because of low 
statistical power, especially in the proportional modeling part 
of our work.
To summarize, we were able to refine and characterize the 
effects of the newly discovered APOC3(rs138326449) loss of 
function mutation in lipoprotein metabolism and its potential to 
affect triglyceride levels. We also characterized the effects of the 
GWAS lead signal in the area of LPL rs12678919 and compared 
its action to that of the APOC3 variant. Our findings suggest that 
the APOC3 variant has a wide range of actions on lipids and 
fatty acids beyond its known effect on triglyceride and HDL. 
Although our novel analyses suggest that much of the action of 
APOC3 on lipids is mediated via LPL action, as hypothesized, 
a parallel intracellular mechanism previously only observed in 
model organisms and cell cultures under conditions mimicking 
pathophysiological disorders also seem to be relevant for the 
composition of VLDL particles. Our results support the results 
of clinical trials on LPL-deficient patients for ISIS 304801, an 
antisense oligonucleotide inhibitor of APOC3 mRNA and, thus, 
illustrate the possible use of such approaches as a relatively 
quick and low-cost tool in the evaluation of drug targets.
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CLINICAL PERSPECTIVE
Plasma triglycerides are robustly associated with atherosclerosis and coronary heart disease. Apolipoprotein C-III (APOC3), 
encoded by the APOC3 gene, is a common component of triglycerides-rich lipoproteins and plays an important role in their 
hydrolysis by lipoprotein lipase and their subsequent uptake into hepatocytes. Loss-of-function APOC3 mutations have 
been associated with lower levels of triglycerides and decreased coronary heart disease risk. Here we studied a rare APOC3 
variant (rs138326449) in participants of 2 European population cohorts measuring a range of metabolic measures, mainly 
lipids associated, using a high-throughput nuclear magnetic resonance metabolomics platform. Among others, the muta-
tion was associated with decreased very low–density lipoprotein and increased high-density lipoprotein and a decrease of 
their triglycerides content. No evidence of association could be established with low-density lipoprotein or other remnant 
cholesterol measures. Comparison between the effects of the APOC3 mutation and the LPL lead signal from GWAS studies 
revealed that they have similar metabolic effects. Two measures for the proportion of triglycerides in large and medium very 
low–density lipoprotein do not completely fit the classic model of APOC3 inhibition of lipoprotein lipase. Our results sup-
port, on an epidemiological level, an alternative intrahepatic role for the mobilization of intracellular triglycerides for larger 
very low–density lipoprotein assembly, as observed in animal models and in vitro experiments under conditions mimicking 
insulin resistance or hypertriglyceridemia, in healthy individuals. This mechanism may be relevant to the action of the ISIS 
304801 antisense oligonucleotide inhibitor of APOC3 mRNA to lower triglycerides in patients with lipoprotein lipase defi-
ciency or hypertriglyceridemia.
